"T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Descriptor ID |
D013601
|
MeSH Number(s) |
A11.118.637.555.567.569 A15.145.229.637.555.567.569 A15.382.490.555.567.569
|
Concept/Terms |
T-Lymphocytes- T-Lymphocytes
- T Lymphocytes
- T-Lymphocyte
- T-Cells
- T Cells
- T-Cell
- Thymus-Dependent Lymphocytes
- Lymphocyte, Thymus-Dependent
- Lymphocytes, Thymus-Dependent
- Thymus Dependent Lymphocytes
- Thymus-Dependent Lymphocyte
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes".
This graph shows the total number of publications written about "T-Lymphocytes" by people in this website by year, and whether "T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 13 | 13 | 26 |
1995 | 20 | 16 | 36 |
1996 | 18 | 7 | 25 |
1997 | 21 | 11 | 32 |
1998 | 22 | 14 | 36 |
1999 | 16 | 13 | 29 |
2000 | 23 | 15 | 38 |
2001 | 22 | 13 | 35 |
2002 | 40 | 25 | 65 |
2003 | 32 | 24 | 56 |
2004 | 32 | 24 | 56 |
2005 | 37 | 32 | 69 |
2006 | 43 | 25 | 68 |
2007 | 41 | 37 | 78 |
2008 | 32 | 31 | 63 |
2009 | 33 | 22 | 55 |
2010 | 32 | 32 | 64 |
2011 | 38 | 31 | 69 |
2012 | 40 | 25 | 65 |
2013 | 32 | 25 | 57 |
2014 | 35 | 8 | 43 |
2015 | 47 | 21 | 68 |
2016 | 35 | 26 | 61 |
2017 | 49 | 45 | 94 |
2018 | 52 | 24 | 76 |
2019 | 39 | 29 | 68 |
2020 | 51 | 33 | 84 |
2021 | 36 | 54 | 90 |
2022 | 14 | 48 | 62 |
2023 | 13 | 73 | 86 |
2024 | 8 | 27 | 35 |
To return to the timeline,
click here.
Below are the most recent publications written about "T-Lymphocytes" by people in Profiles.
-
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults. Blood Adv. 2024 Jul 09; 8(13):3544-3548.
-
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
-
Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma. Blood Adv. 2024 Jul 09; 8(13):3360-3371.
-
The effect of ADAMTS13 on graft-versus-host disease. J Cell Mol Med. 2024 Jul; 28(13):e18457.
-
CAR T-cell expansion: harmful or helpful? Blood Adv. 2024 Jun 25; 8(12):3311-3313.
-
Integration of ?-deficient CARs into the CD3? gene conveys potent cytotoxicity in T and NK cells. Blood. 2024 Jun 20; 143(25):2599-2611.
-
Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application? Haematologica. 2024 Jun 01; 109(6):1656-1667.
-
Reactivity of HLADR antibody manifests expression of surface MHC II molecules on peripheral blood T lymphocytes in new world monkeys. Immun Inflamm Dis. 2024 Jun; 12(6):e1318.
-
6-Formylindolo[3,2-b]carbazole, a potent ligand for the aryl hydrocarbon receptor, attenuates concanavalin-induced hepatitis by limiting T-cell activation and infiltration of proinflammatory CD11b+ Kupffer cells. J Leukoc Biol. 2024 May 29; 115(6):1070-1083.
-
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile. Blood Adv. 2024 May 14; 8(9):2059-2073.